<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30411340</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>09</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1097-0215</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Nov</Month>                        <Day>08</Day>                    </PubDate>                </JournalIssue>                <Title>International journal of cancer</Title>                <ISOAbbreviation>Int. J. Cancer</ISOAbbreviation>            </Journal>            <ArticleTitle>Comorbidities, age and period of diagnosis influence treatment and outcomes in early breast cancer.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1002/ijc.31974</ELocationID>            <Abstract>                <AbstractText>Survival for breast cancer (BC) is lower in eastern than northern/central Europe, and in older than younger women. We analysed how comorbidities at diagnosis affected whether selected standard treatments (STs) were given, across Europe and over time, also assessing consequences for survival/relapse. We analysed 7,581 stage I/IIA cases diagnosed in 9 European countries in 2009-13, and 4 STs: surgery; breast-conserving surgery plus radiotherapy (BCS+RT); reconstruction after mastectomy; and prompt treatment (≤6 weeks after diagnosis). Covariate-adjusted models estimated odds of receiving STs and risks of death/relapse, according to comorbidities. Pearson's R assessed correlations between odds and risks. The z-test assessed the significance of time-trends. Most women received surgery: 72% BCS; 24% mastectomy. Mastectomied patients were older with more comorbidities than BCS patients (P&lt;0.001). Women given breast reconstruction (25% of mastectomies) were younger with fewer comorbidities than those without reconstruction (P&lt;0.001). Women treated promptly (45%) were younger than those treated later (P=0.001), and more often without comorbidities (P&lt;0.001). Receiving surgery/BCS+RT correlated strongly (R=-0.9), but prompt treatment weakly (R=-0.01/-0.02), with reduced death/relapse risks. The proportion receiving BCS+RT increased significantly (P&lt;0.001) with time in most countries. This appears to be the first analysis of the influence of comorbidities on receiving STs, and of consequences for outcomes. Increase in BCS+RT with time is encouraging. Although women without comorbidities usually received STs, elderly patients often received non-standard less prompt treatments, irrespective of comorbidities, with increased risk of mortality/relapse. All women, particularly the elderly, should receive ST wherever possible to maximize the benefits of modern evidence-based treatments.</AbstractText>                <CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Minicozzi</LastName>                    <ForeName>Pamela</ForeName>                    <Initials>P</Initials>                    <Identifier Source="ORCID">https://orcid.org/0000-0002-7273-7947</Identifier>                    <AffiliationInfo>                        <Affiliation>Analytical Epidemiology and Health Impact Unit, Research Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Van Eycken</LastName>                    <ForeName>Liesbet</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Research Department, Belgian Cancer Registry, Brussels, Belgium.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Molinie</LastName>                    <ForeName>Florence</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Loire-Atlantique/Vendée Cancer Registry, Nantes, France.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>SIRIC-ILIAD, CHU Nantes, Nantes, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Innos</LastName>                    <ForeName>Kaire</ForeName>                    <Initials>K</Initials>                    <Identifier Source="ORCID">https://orcid.org/0000-0003-0120-2213</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Epidemiology and Biostatistics, National Institute for Health Development, Tallinn, Estonia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Guevara</LastName>                    <ForeName>Marcela</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Navarra Cancer Registry, Public Health Institute of Navarra, IDISNA, Pamplona, Spain.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Marcos-Gragera</LastName>                    <ForeName>Rafael</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Epidemiology Unit and Girona Cancer Registry, Department of Health, Catalan Institute of Oncology (ICO), Girona, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Castro</LastName>                    <ForeName>Clara</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Epidemiology, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>EpiUnit, Institute of Public Health, University of Porto, Porto, Portugal.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Rapiti</LastName>                    <ForeName>Elisabetta</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Geneva Cancer Registry, Global Health Institute, University of Geneva, Geneva, Switzerland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Katalinic</LastName>                    <ForeName>Alexander</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>University of Lübeck, Institute for Social Medicine and Epidemiology, Lübeck, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Torrella</LastName>                    <ForeName>Ana</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Castellón Cancer Registry, Epidemiology Unit, Public Health Department, Castellón, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Žagar</LastName>                    <ForeName>Tina</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Epidemiology and Cancer Registry, Institute of Oncology Ljubljana, Ljubljana, Slovenia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bielska-Lasota</LastName>                    <ForeName>Magdalena</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Health Promotion and Prevention of Chronic Diseases, National Institute of Public Health (NIH), Warsaw, Poland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Rossi</LastName>                    <ForeName>Paolo Giorgi</ForeName>                    <Initials>PG</Initials>                    <AffiliationInfo>                        <Affiliation>Epidemiology Unit, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Reggio Emilia, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Larrañaga</LastName>                    <ForeName>Nerea</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Public Health Department of Gipuzkoa, Donostia, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bastos</LastName>                    <ForeName>Joana</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>EpiUnit, Institute of Public Health, University of Porto, Porto, Portugal.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Portuguese Institute of Oncology Francisco Gentil (IPO Coimbra), Coimbra, Portugal.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sánchez</LastName>                    <ForeName>Maria José</ForeName>                    <Initials>MJ</Initials>                    <AffiliationInfo>                        <Affiliation>Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Andalusian School of Public Health, Granada Cancer Registry, Granada, Spain.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Biomedical Research Institute of Granada (ibs.Granada), Granada, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sant</LastName>                    <ForeName>Milena</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Analytical Epidemiology and Health Impact Unit, Research Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <CollectiveName>European HR Working Group on breast cancer</CollectiveName>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>11</Month>                <Day>08</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Int J Cancer</MedlineTA>            <NlmUniqueID>0042124</NlmUniqueID>            <ISSNLinking>0020-7136</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">comorbidities</Keyword>            <Keyword MajorTopicYN="N">early breast cancer</Keyword>            <Keyword MajorTopicYN="N">outcomes</Keyword>            <Keyword MajorTopicYN="N">population study</Keyword>            <Keyword MajorTopicYN="N">standard treatment</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>06</Month>                <Day>28</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>09</Month>                <Day>26</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>10</Month>                <Day>23</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>11</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>11</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30411340</ArticleId>            <ArticleId IdType="doi">10.1002/ijc.31974</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>